80
Participants
Start Date
March 1, 2019
Primary Completion Date
March 1, 2020
Study Completion Date
April 1, 2020
Saxagliptin 5mg
Patients would be assigned to saxagliptin (Onglyza® AstraZeneca Pharmaceuticals LP, Indiana, USA), either received a dose of 5 mg or 2.5 mg daily if patients had eGFR \<50 mL/min/1.73 m2
Faculty of Pharmacy, Al Qāhirah al Jadīdah
Beni-Suef University
OTHER